Gamifant (emapalumab-lzsg) / SOBI  >>  Phase 2
Welcome,         Profile    Billing    Logout  

6 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gamifant (emapalumab-lzsg) / SOBI
2012-005753-23: A study to investigate the long-term safety and efficacy of a new drug, NI-0501, in children with a disease that is called "Haemophagocytic Lymphohistiocytosis".

Completed
2
55
Europe, RoW
emapalumab, NI-0501, Concentrate for solution for infusion
NovImmune SA, Novimmune SA, NovImmune SA, Seventh Framework Programme for Research, Novimmune SA
Haemophagocytic lymphohistiocytosis, A rare, life-threatening condition affecting predominantly children. The disease is characterized by uncontrolled inflammation., Diseases [C] - Immune System Diseases [C20]
 
 
NCT03311854 / 2016-004223-23: A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)

Completed
2
14
Europe, US
Emapalumab, Gamifant
Swedish Orphan Biovitrum
Macrophage Activation Syndrome, Lymphohistiocytosis, Hemophagocytic, Arthritis, Juvenile, Adult Onset Still Disease
05/20
05/20
NCT04731298: Study to Investigate the Pharmacokinetics, Pharmacodynamics and Assess the Efficacy and Safety to Support Dose Selection of Emapalumab in Pre-empting Graft Failure in Patients at High Risk After HSCT.

Terminated
2
2
Canada, RoW
Emapalumab, Gamifant®, NI-0501
Swedish Orphan Biovitrum, PRA Health Sciences, Cytel Inc., Q2 Solutions, ABF Pharmaceutical Services GmbH, Cromsource, BioMérieux
Graft Failure
04/22
04/22
NCT06430788: A Study of Emapalumab for Pediatric Aplastic Anemia

Recruiting
2
55
US
Emapalumab, Gamifant
Memorial Sloan Kettering Cancer Center
Aplastic Anemia, Cytopenia, Hypocellular Marrow
05/29
05/29
BRIDGE, NCT05787574: A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition

Recruiting
2
39
US
Emapalumab, Fludarabine and Dexamethasone, Stem Cell Transplant
Memorial Sloan Kettering Cancer Center, Sobi, Inc.
Primary Immune Regulatory Disorder, Autoimmune Lymphoproliferative, Immune System Diseases
03/27
03/27
NCT05463133: Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists

Recruiting
1/2
50
US
Sirolimus, Cyclophosphamide, Alemtuzumab, Busulfan, Pheripheral blood stem cells, Emapalumab-Izsg, Tociluzumab, Total Body Irradiation
National Institute of Allergy and Infectious Diseases (NIAID)
Chronic Granulomatous Disease
12/32
12/32

Download Options